The combination of T-Dxd and nivolumab demonstrated significant efficacy in second- and later-line treatment of HER2-expressing urothelial carcinoma(DCR 76.6%, mPFS 6.9 months, mOS 11.0 months); however, it was associated with a notable incidence of serious adverse events (AEs ) [148]. This evidence concerns the gene ERBB2 and urothelial carcinoma.